A Phase II Study Evaluating the Use of Donated EBV-Immune T Cells to Treat Transplant Recipients with EBV

Full Title

A Phase II Study of The Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From A Normal HLA- Compatible Or Partially- Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies


Epstein-Barr virus (EBV) is common and normally poses little risk to healthy people. However, EBV can cause complications in patients whose immune systems have been weakened, such as recipients of bone marrow, heart, lung, or kidney transplants. Such complications include lymphoma or other EBV-related cancers. Other people can also develop cancers related to EBV, including patients with genetic or drug-induced immune-deficiency diseases.

In this study, researchers are finding out whether giving white blood cells called T cells that are immune to EBV can be used to treat patients with EBV-related cancers and other EBV-related problems. Patients in this study include those with EBV that did not respond to standard therapy.

Patients will receive EBV-immune T cells from a bank of healthy “third-party” donors (someone not related to the patient, or a donor who previously gave blood or tissue to the patient) who are ¿partially matched¿ to the patient’s tissue type.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have EBV-related cancer, other EBV-related disease, or evidence of EBV in their white blood cells after transplant.
  • There must be no other standard treatment available, or patients must have demonstrated a lack of response to prior treatment.
  • Patients of all ages are eligible to participate.

For more information about this study and to inquire about eligibility, please contact Dr. Susan Prockop at 212-639-6715.